Abstract: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.

Abstract: A method of treating dry age related macular degeneration (“AMD”) comprising administration to the eye of an individual in need thereof of a therapeutically effective amount of an anti-endoglin agent.

Abstract: Compositions and methods related to ophthalmic use of polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.

Abstract: Systems, compositions, methods, and kits for identifying potential therapeutic agents for treatment of complement based ocular diseases are provided herein. The methods and kits include a complement component 3 (C3) protein or derivative that is contacted to ocular cells or tissue. Another embodiment of the invention herein provides for diagnosis and/or prognosis of a complement-associated ocular disease. Compositions, methods and kits for regulating or treating a complement-related condition using at least one of CD46 protein, CD55 protein, and a recombinant chimeric soluble terminator of activated complement (STAC) protein or source of the STAC protein. The STAC protein includes an amino acid sequence including at least two of an amino acid sequence of a CD59 protein, an amino acid sequence derived from a CD46 protein, and an amino acid sequence derived from a CD55 protein, optionally further comprising a linker to connect amino acid sequences.

Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.

Abstract: The present invention relates to a recombinant protein for siRNA delivery, which allows the efficient intracellular and in vivo delivery of siRNA. More particularly, the present invention relates to a recombinant protein that allows a siRNA binding protein to be located in the interior cavity of a capsid protein of HBV (Hepatitis B virus), in which siRNAs of interest bind to the siRNA binding protein to be encapsulated within the capsid shell, thereby providing stability against the external attack such as nucleases and achieving the efficient intracellular and in vivo delivery of siRNA by its release into the cytosolic space after cell uptake.

Abstract: Therapeutic and cosmetic uses and applications of calreticulin are provided. In particular, the invention relates to therapeutic and cosmetic uses and applications of calreticulin to a patient in need of such treatment including in tissue repair, wound healing, ulcers, reducing scar formation, and reducing or eliminating wrinkles.

Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.

Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.

Abstract: An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer-lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant.

Abstract: Described herein is the synthesis of adhesive complex coacervates from electrostatically associated block copolymers, wherein the block copolymers comprise alternating polycationic and polyanionic blocks. Methods for making and the using the adhesive complex coacervates are also described herein.

Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Abstract: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.

Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.

Abstract: The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6.

Abstract: Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.

Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.

Abstract: Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.

Abstract: Methods and compositions for stabilizing opsin protein in a vertebrate visual system are provided by administration of opsin-binding synthetic retinoids.

Abstract: The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.

Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.

Abstract: The invention provides parstatin peptides, particularly a mammalian parstatin peptide including amino acids 1-26 of full length mammalian parstatin, preferably a human parstatin. The invention provides parstatin peptides in appropriate pharmaceutical carriers and formulated for administration. The invention provides for the use of the peptide for example as a medicament or for the preparation of a medicament. The invention provides methods of use for parstatin peptides including for inhibition of angiogenesis, for example for inhibition of ocular angiogenesis, for methods of cardioprotection, and for methods of prevention and treatment of myocardial ischemia-reperfusion injury.

Abstract: Methods of stabilizing and organizing collagen fibrils in extracellular matrix of retinal tissues, particularly Bruch's membranes, and stabilizing retinal pigment epithelial layers lining Bruch's membrane are disclosed. The stabilization and organization may be effected by treating retinal tissues with a protein that crosslinks and organizes collagen fibrils, such as decorin. The stabilization and organization methods include treatment of retinal tissues before, during, or after diagnosis of dry macular degeneration, diagnosis of early stages of diabetic retinopathy and diabetic macular edema to prevent, retard, or limit progression of disorganization of Bruch's membrane and disorganization of retinal pigment epithelial cells lining Bruch's membrane.

Abstract: Described herein are materials and methods of treating dry eye disease in a subject.

Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.

Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.

Abstract: This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound binding to connective tissue growth factor.

Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline

Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

Abstract: Peptides and their functionally equivalent derivatives, in salt form or non-salt form, effective in the treatment and prevention of tumor, with the general formula L1-X1-X2-X3-X4, wherein: L1 is H, or acyl, or any natural or non-natural amino acid; X2 is any natural or non-natural amino acid, optionally N-alkylated and/or C?-alkylated; X4 is any natural or non-natural hydrophobic amino acid, optionally C?-alkylated and/or amidated at the C-terminal end, or any hydrophobic amino alcohol, or a hydrophobic gem-diamine, optionally N?-alkylated or N?-acylated.

Abstract: The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis.

Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).

Abstract: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.

Abstract: The present invention relates to methods of treating dry eye using ?-turn peptidomimetic cyclic compounds or derivatives thereof. The ?-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye.

Abstract: The invention refers to the use of transforming growth factor-beta 1 (TGF-?1) inhibitor peptides or polynucleotides encoding said peptides for the prevention and/or treatment of corneal fibrosis and/or corneal haze.

Abstract: A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells.

Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.

Abstract: Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.

Abstract: Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.

Abstract: Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.

Abstract: The present invention generally features novel cosmetic skin and hair care compositions for enhancing the appearance of eyelashes and eyebrows. Specifically, the topical skin and hair care compositions of the invention contain a concentration of at least one of pentapeptide-17 tetrapeptide-12 that provide for thicker, longer and more voluminous appearing eyelashes and eyebrows. The cosmetic formulations of the invention may further include cosmetically acceptable vehicle(s) and/or other skin and hair conditioning agents.

Abstract: The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system or feverless response to infection. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers.

Abstract: Compositions for antagonizing phosphorylation and subsequent degradation of glycogen synthase kinase 3 beta (GSK3?) in epidermal cells are disclosed. GSK3? phosphorylation antagonists include molecules that function to inhibit or reduce the binding activity or enzymatic activity of an upstream signaling molecule leading to GSK3? phosphorylation, or by downregulating the expression of one or more upstream signaling molecules involved in regulating GSK3? phosphorylation. Methods of using the GSK3? phosphorylation antagonists to inhibit or reduce the phosphorylation and degradation of GSK3? in epidermal cells are provided. The methods are useful to promote epithelialization and closure of wounds, such as chronic non-healing wounds.

Abstract: A process of detecting the presence of or susceptibility to a disease involving the Frizzled-4 receptor is provided. The inventive method determines the presence or absence of one or more mutations in Frizzled-4 alone or in conjunction with other proteins such as Norrin and LRP5. The presence of a mutation predicts the presence of a disease or susceptibility to a disease. The inventive process further provides correction or prevention of a disease by administration of frizzled-4 to a subject to alter or maintain a physiological function.

Abstract: The invention relates to a cosmetic and/or pharmaceutical composition comprising, in a physiologically suitable medium, a carob peptide extract (Ceratonia siliqua L.) as an active agent for promoting aquaporin expression. The present invention also relates to the use of a carob peptide extract (Ceratonia siliqua L.), as an active agent for promoting aquaporin expression, in a cosmetic composition for improving the moisturization and the barrier function of the epidermis and for stimulating skin regeneration. The invention also relates to the use of this novel active agent for preparing a pharmaceutical, in particular dermatological, composition for regulating and/or stimulating aquaporin activity. The invention also relates to a cosmetic treatment method for preventing or combating dryness of the skin and mucous membranes and the manifestations of skin aging.

Abstract: We provide methods and compositions for the treatment of dysregulation of blood vessel growth by regulation of neovascularization. Embodiments accomplish this by restricting the diffusion and transport of therapeutic agents through conjugating them to polymers or polymer constructs while retaining the binding affinities and functions of the therapeutic agents.

Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are ?-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property to antagonize the receptor CCR10. They can be used as medicaments to treat or prevent diseases or conditions in the area of dermatological and cutaneous disorders, inflammation, allergic disorders, respiratory diseases, diseases of the gastro-intestinal tract, ophthalmic diseases, haematology and cancer. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.

Abstract: The invention relates to a method for modulating neovascularisation of a tissue in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound or a combination of compounds selected from an isolated nucleic acid molecule comprising a gene selected from the group consisting of RIKEN c DNA S9430020K01, Agtrl1, Apelin, Stabilin 1, Stabilin 2, TNFaip8l1, TNFaip8 and FGD5, and homologues thereof; a gene product encoded by said genes, or encoded by homologues of these genes, and functional fragments thereof; an antibody or derivative thereof directed against a gene product of said genes, or encoded by homologues of these genes, and functional fragments thereof, said derivative preferably being selected from the group consisting of scFv fragments, Fab fragments, chimeric antibodies, bifunctional antibodies, intrabodies, and other antibody-derived molecules; an antisense molecule, in particular an antisense RNA or antisense oligodeoxynucleotide, an